MX2015012302A - Composiciones tópicas y métodos de tratamiento para trastornos de la piel. - Google Patents

Composiciones tópicas y métodos de tratamiento para trastornos de la piel.

Info

Publication number
MX2015012302A
MX2015012302A MX2015012302A MX2015012302A MX2015012302A MX 2015012302 A MX2015012302 A MX 2015012302A MX 2015012302 A MX2015012302 A MX 2015012302A MX 2015012302 A MX2015012302 A MX 2015012302A MX 2015012302 A MX2015012302 A MX 2015012302A
Authority
MX
Mexico
Prior art keywords
topical
body surface
film
treatment
methods
Prior art date
Application number
MX2015012302A
Other languages
English (en)
Inventor
Evgania Lozinsky
Eran Eilat
Original Assignee
Peritech Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peritech Pharma Ltd filed Critical Peritech Pharma Ltd
Publication of MX2015012302A publication Critical patent/MX2015012302A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Abstract

Una composición tópica incluye al menos un ingrediente de formación de película; al menos un surfactante; al menos un solvente de siloxano volátil no polar; al menos 15% (p/p) agua; y una concentración terapéuticamente efectiva de al menos un agente farmacéutico, en donde la composición está para secarse 60 segundos después de la aplicación a una superficie del cuerpo para formar una composición seca, y en donde la composición seca forma: una película flexible, en donde la película flexible sigue de cerca las irregularidades de la superficie del cuerpo y (ii) una película durable, en donde la película durable no se cuartea ni forma escamas permaneciendo intacta por más de 12 horas liberando el agente farmacéutico por un periodo de tiempo prolongado.
MX2015012302A 2013-03-10 2014-03-10 Composiciones tópicas y métodos de tratamiento para trastornos de la piel. MX2015012302A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361775598P 2013-03-10 2013-03-10
PCT/IB2014/001233 WO2014140925A2 (en) 2013-03-10 2014-03-10 Topical compositions and methods of treatment of topical disorders

Publications (1)

Publication Number Publication Date
MX2015012302A true MX2015012302A (es) 2016-06-21

Family

ID=51488109

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012302A MX2015012302A (es) 2013-03-10 2014-03-10 Composiciones tópicas y métodos de tratamiento para trastornos de la piel.

Country Status (12)

Country Link
US (5) US9072747B2 (es)
EP (1) EP2968133A4 (es)
JP (1) JP2016510807A (es)
KR (1) KR20150136077A (es)
CN (1) CN105142611B (es)
AU (1) AU2014229497A1 (es)
BR (1) BR112015022223B1 (es)
CA (1) CA2904507C (es)
IL (1) IL241191B (es)
MX (1) MX2015012302A (es)
RU (1) RU2670750C9 (es)
WO (1) WO2014140925A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9072747B2 (en) 2013-03-10 2015-07-07 Peritech Pharma Ltd. Topical compositions and methods of treatment of anorectal disorders
WO2014183055A1 (en) * 2013-05-10 2014-11-13 M. Alphabet 2, L.L.C. Methods of treating skin conditions using cyclolignan compounds
US20150366798A1 (en) * 2014-06-19 2015-12-24 Evgenia Lozinsky Pharmaceutical adhesive compositions for treatment of epistaxis and methods of use thereof
WO2016018473A1 (en) * 2014-07-31 2016-02-04 Kimberly-Clark Worldwide, Inc. Anti-adherent composition
CA2952818A1 (en) * 2015-05-01 2016-11-10 Eran Eilat Compositions for the treatment of epistaxis
EP3331888A4 (en) * 2015-08-03 2019-03-20 Synergistic Therapeutics, LLC THERAPEUTIC GEL FOR SEXUAL DYSFUNCTION
WO2017040420A1 (en) * 2015-08-28 2017-03-09 C.B. Fleet Company, Incorporated Hemorrhoid preparation and sheets
MX2019004576A (es) * 2016-10-21 2019-09-16 Crescita Therapeutics Inc Composiciones farmaceuticas.
WO2019064165A1 (en) * 2017-09-28 2019-04-04 Zenvision Pharma Llp SYNERGISTIC PHARMACEUTICAL COMPOSITION OF ACYCLOVIR OR PENCICLOVIR, DOCOSANOL AND HYDROCORTISONE
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
AT521126A2 (de) * 2018-03-29 2019-10-15 Bcsk Biocid Gmbh Sprühpflasterzusammensetzung
EP3955918A1 (en) 2019-04-17 2022-02-23 COMPASS Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
US11246872B2 (en) 2019-06-14 2022-02-15 Propella Therapeutics, Inc. Topical acyclovir formulations and uses thereof
WO2021067626A2 (en) 2019-10-01 2021-04-08 Intima Bioscience, Inc. Genetic engineering of fungi to modulate tryptamine expression
CN110585312A (zh) * 2019-10-18 2019-12-20 北京博达绿洲医药科技研究有限公司 利多去氧乳膏及其制备方法和用途
CN111374938B (zh) * 2020-03-19 2020-12-22 广州杨森药业有限公司 一种含壬二酸的无油凝胶剂及其制备方法
US20230219889A1 (en) 2020-05-19 2023-07-13 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
CA3085078A1 (en) * 2020-06-29 2021-12-29 Napoleon Savescu Medicament, compound, composition and method for treating herpes
JP2024512791A (ja) * 2021-04-01 2024-03-19 スティール セラピューティクス，インク． ニフェジピンとリドカインとを含む局所用ワイプ
WO2023172216A1 (en) * 2022-03-11 2023-09-14 Ilko Ilac Sanayi Ve Ticaret A.S. Hydrocortisone and pramoxine topical formulations having enhanced in-vitro release
CN115518031A (zh) * 2022-10-28 2022-12-27 云飞生物药业(吉林)有限公司 一种卡波姆痔疮凝胶

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3527224A (en) 1967-09-05 1970-09-08 American Cyanamid Co Method of surgically bonding tissue together
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4613498A (en) 1984-10-24 1986-09-23 Frank Crosby Hemorrhoid medication
US4626433A (en) 1985-05-20 1986-12-02 Preparation Gold, Inc. Remedy for hemorrhoids
US4797392A (en) 1987-01-27 1989-01-10 Chernomorsky Simon A Use of anorectal compositions
US4987893A (en) 1988-10-12 1991-01-29 Rochal Industries, Inc. Conformable bandage and coating material
US5103812A (en) 1988-10-12 1992-04-14 Rochal Industries, Inc. Conformable bandage and coating material
ES2031245T3 (es) 1988-11-08 1992-12-01 Sekisui-Iko Company Ltd. Aplicador de adhesivo.
US5756747A (en) 1989-02-27 1998-05-26 Riker Laboratories, Inc. 1H-imidazo 4,5-c!quinolin-4-amines
US5166132A (en) 1989-03-23 1992-11-24 Gordon Arthur L Healing composition employing an enzyme-modified casein
US5219880A (en) 1991-03-29 1993-06-15 Dermatologic Research Corporation Treatment of viral tumors and hemorrhoids with artemisinin and derivatives
US5130124A (en) 1991-05-01 1992-07-14 Isp Investments Inc. Stabilized, aqueous, film-forming antimicrobial compositions of hydrogen peroxide
US5234914A (en) 1991-06-11 1993-08-10 Patent Biopharmaceutics, Inc. Methods of treating hemorrhoids and anorecial disease
US5627216A (en) 1994-02-07 1997-05-06 Papadopoulos; George D. Medicinal ointment for hemorrhoid and skin care
GB9406854D0 (en) 1994-04-07 1994-06-01 Gillette Co Antiperspirants
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
WO1997044001A1 (fr) * 1996-05-20 1997-11-27 Shiseido Co., Ltd. Composition d'emulsion aqueuse et emulsifiant aqueux
US6387405B1 (en) * 1998-02-27 2002-05-14 E-L Management Corp. Velvety hydrocarbon based cosmetic compositions
EP0966972B1 (en) * 1998-06-18 2003-09-24 Dow Corning France S.A. Topical composition containing silicon gum
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
DE69933775T2 (de) 1998-08-20 2007-10-04 3M Innovative Properties Co., St. Paul Sprühverband und wirkstoffabgabesystem
MXPA01009653A (es) 1999-03-25 2002-05-14 3M Innovative Properties Co Composicion de recubrimiento anti-picadura.
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
GB9913408D0 (en) 1999-06-10 1999-08-11 Albright & Wilson Uk Ltd Personal care formulations
US20020192273A1 (en) 2001-06-15 2002-12-19 Teri Buseman Therapeutic patch useful for the treatment of hemorrhoids
US6833139B1 (en) 2002-01-09 2004-12-21 Ferndale Laboratories, Inc. Composition and method for the treatment of anorectal disorders
US7879316B2 (en) 2002-06-12 2011-02-01 L'oreal Cosmetic composition containing a polyorganosiloxane polymer
US6821523B2 (en) 2002-06-21 2004-11-23 Dermatrends, Inc. Topical administration of pharmacologically active bases in the treatment of warts
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
BRPI0407010A (pt) 2003-01-29 2006-01-10 Unilever Nv Composição cosmética de limpeza, método para tratamento cosmético, sistema cosmético, composição de limpeza e processo para a produção de um sistema
US20040235807A1 (en) 2003-05-21 2004-11-25 Weinrich Karl P. Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea
IL156670A0 (en) 2003-06-26 2004-01-04 Zvi Zolotariov Aloe suppositories
DE602004019956D1 (de) 2003-10-27 2009-04-23 Dow Corning Zubereitungen für die topische anwendung und verfahren zur abgabe eines wirkstoffs an ein substrat
US8022106B2 (en) 2004-03-04 2011-09-20 Ferring B.V. Tranexamic acid formulations
US20060004094A1 (en) * 2004-07-02 2006-01-05 Agisim Gary R Composition and method for treating hemorrhoids and/or anorectal disorders
RU2277926C2 (ru) * 2004-07-08 2006-06-20 Общество с ограниченной ответственностью "Медицинское научно-производственное объединение "Биокон" Лекарственная композиция для локального лечения геморроя, трещин анального отверстия и воспалительных заболеваний слизистой оболочки прямой кишки
CN101001649B (zh) 2004-07-09 2011-08-31 弗罗桑医疗设备公司 包括透明质酸的止血组合物及其制备方法
US20060105028A1 (en) 2004-11-12 2006-05-18 Jie Zhang Systems and methods for treating warts
US20060110415A1 (en) * 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
US7318937B2 (en) 2005-03-18 2008-01-15 Closure Medical Corporation Liquid coating compositions
WO2007002880A2 (en) 2005-06-29 2007-01-04 Jr Chem, Llc Method of enhanced drug application
EP1976956B1 (en) 2006-01-19 2014-05-07 Dow Corning Corporation Silicone adhesive for adhesion to wet surfaces
DE102006020382A1 (de) * 2006-04-28 2007-10-31 Henkel Kgaa Schnell trocknende kosmetische Emulsionen zur Roll-on-Applikation
US20080014252A1 (en) * 2006-07-14 2008-01-17 Delprete Keith Topical compositions with long lasting effect
WO2008018644A1 (en) 2006-08-09 2008-02-14 Stc Nara Co., Ltd. Cosmetic compositions for improving the performance of transfer-resistant and long-wearing
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US7742730B2 (en) * 2007-10-26 2010-06-22 Xerox Corporation Control to detect air knife blockage
WO2009082511A1 (en) * 2007-12-20 2009-07-02 Elc Management Llc Methods and compositions for treating skin
IN2012DN00942A (es) 2009-07-03 2015-04-03 Dow Corning
EP2492333B1 (en) 2009-10-23 2014-04-30 Dow Corning Toray Co., Ltd. Thickening or gelling agent for oily raw materials
WO2011053801A2 (en) 2009-10-30 2011-05-05 Intratus, Inc. Methods and cosmetic preparations for the sustained delivery of therapeutic agents to the eye
US20150231300A1 (en) 2012-10-28 2015-08-20 Peritech Pharma Ltd. Pharmaceutical liquid adhesive compositions for treatment of anorectal disorders
US9072747B2 (en) 2013-03-10 2015-07-07 Peritech Pharma Ltd. Topical compositions and methods of treatment of anorectal disorders
US10981961B2 (en) 2013-03-11 2021-04-20 University Of Florida Research Foundation, Incorporated Delivery of card protein as therapy for occular inflammation
US20150366798A1 (en) 2014-06-19 2015-12-24 Evgenia Lozinsky Pharmaceutical adhesive compositions for treatment of epistaxis and methods of use thereof

Also Published As

Publication number Publication date
CN105142611B (zh) 2019-06-04
CA2904507A1 (en) 2014-09-18
JP2016510807A (ja) 2016-04-11
EP2968133A2 (en) 2016-01-20
US20140255522A1 (en) 2014-09-11
BR112015022223A2 (pt) 2017-07-18
US10085995B2 (en) 2018-10-02
CN105142611A (zh) 2015-12-09
RU2015143158A (ru) 2017-04-18
US10085994B2 (en) 2018-10-02
IL241191B (en) 2020-02-27
US20140256688A1 (en) 2014-09-11
WO2014140925A2 (en) 2014-09-18
RU2670750C2 (ru) 2018-10-25
KR20150136077A (ko) 2015-12-04
US20150272957A1 (en) 2015-10-01
BR112015022223B1 (pt) 2022-06-28
WO2014140925A3 (en) 2015-07-30
US9072747B2 (en) 2015-07-07
AU2014229497A1 (en) 2015-09-24
US20140255521A1 (en) 2014-09-11
IL241191A0 (en) 2015-11-30
RU2015143158A3 (es) 2018-03-20
CA2904507C (en) 2021-05-04
RU2670750C9 (ru) 2018-12-13
EP2968133A4 (en) 2016-03-09
US20180344743A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
MX2015012302A (es) Composiciones tópicas y métodos de tratamiento para trastornos de la piel.
MA51103A (fr) Compositions et procédés de traitement de l'atrophie musculaire et de la dystrophie myotonique
MX2017006832A (es) Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
MX2022014313A (es) Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada.
CR20190063A (es) 3-metil pirazinas 2,5-disustituídas y 3-metil pirazinas 2,5,6-trisustituídas como inhibidores alostéricos de shp2
WO2015104292A3 (en) Compounds for use in treating or preventing cancerous diseases
WO2017042607A3 (en) Compositions comprising meloxicam-cyclodextrin inclusion complexes and methods of treating acute pain
EA201690962A1 (ru) Составы
EP4299122A3 (en) Compositions and methods for treating skin and mucous membrane diseases
UY32456A (es) Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento
BR112015021888A2 (pt) inibidores de dna-ik
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
AR081789A1 (es) Composiciones y metodos para estimular magp-1 y mejorar la apariencia de la piel
CR20150432A (es) Estra-1,3,5 (10), 16-tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
ECSP11011082A (es) Compuestos, composición farmaceutica y métodos para utilizarse en el tratamiento de desórdenes metabólicos
WO2014169078A3 (en) 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
RS54584B1 (en) 15-HEPE PREPARATIONS AND PROCEDURES FOR THEIR USE
CL2014001838A1 (es) Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras.
BR112017009980A2 (pt) ?sistema e método para prevenção de alopecia?.
EP4249431A3 (en) Compositions and methods for treating diseases or disorders using extended release nitric oxide releasing solutions
BR112017016084A2 (pt) composição e método para o tratamento da doença veno-oclusiva hepática
BR112016029996A2 (pt) utilização cosmética, composição e método cosmético para tratar os odores corporais
MX2022015456A (es) Composiciones de maca y metodos de uso.